BARCELONA, Spain--(BUSINESS WIRE)--Massive Bio, a global leader in artificial intelligence (AI) for cancer clinical trial enrollment, has announced the launch of Patient Connect, an innovative and free portal designed to help cancer patients navigate their clinical trial journey across the globe.

西班牙巴塞罗那--（商业新闻短讯）--癌症临床试验注册人工智能（AI）领域的全球领导者Massive Bio宣布推出Patient Connect，这是一个创新的免费门户网站，旨在帮助癌症患者在全球范围内进行临床试验。

Massive Bio Patient Connect empowers patients and simplifies their search for the right clinical trial, in the language of their choice. By providing consented access to their medical records, patients enable an in-depth analysis using Massive Bio’s AI-powered multi-trial matching system, allowing them to identify the best clinical trial options based on their specific diagnosis, biomarkers, treatment history and geographic location.

Massive Bio-Patient Connect以患者选择的语言为患者提供了强大的能力，简化了他们对正确临床试验的搜索。通过提供对其医疗记录的同意访问，患者可以使用Massive Bio的AI支持的多试验匹配系统进行深入分析，使他们能够根据其特定诊断，生物标志物，治疗史和地理位置确定最佳的临床试验选择。

This approach is designed to expand access to treatment possibilities, regardless of financial or geographical constraints. Patients can also download their personalized clinical trial matching reports and share their results with their physicians and loved ones, enabling them to make better informed decisions about their cancer care..

这种方法旨在扩大获得治疗的可能性，而不受财政或地理限制。患者还可以下载他们的个性化临床试验匹配报告，并与他们的医生和亲人分享他们的结果，使他们能够对癌症护理做出更明智的决定。。

Simply by signing up, Patient Connect now allows over 132,000 patients on-boarded by Massive Bio to access their own personal matching results for nearly 16,000 cancer trials. To date, Massive Bio has successfully matched patients to over 33,000 clinical trial sites, demonstrating the scalability of their cutting-edge AI platform.

通过注册，Patient Connect现在可以让Massive Bio登机的132000多名患者获得近16000项癌症试验的个人匹配结果。迄今为止，Massive Bio已成功将患者匹配到33000多个临床试验地点，证明了其尖端AI平台的可扩展性。

And, in a recent publication at ASCO 2024, Massive Bio, in collaboration with the Precision Cancer Consortium, showed that their unique multi-trial matching approach results in up to 12-fold increase in patient eligibility for a clinical trial..

此外，在ASCO 2024的最新出版物中，Massive Bio与Precision Cancer Consortium合作显示，他们独特的多试验匹配方法使患者的临床试验资格提高了12倍。。

Dr. Arturo Loaiza-Bonilla, Chief Medical Officer and Co-Founder of Massive Bio stated that, “Patient Connect redefines how patients engage with clinical trials, offering them a lifeline to new treatment possibilities and hope for better outcomes.'

Massive Bio首席医疗官兼联合创始人Arturo Loaiza Bonilla博士表示，“患者连接重新定义了患者如何参与临床试验，为他们提供了新治疗可能性的生命线，并希望取得更好的结果。”

In addition to technological solutions, Massive Bio offers personalized support through its concierge services. Once referred, Massive Bio’s patient relations coordinators, MDs and oncology nurses work closely with patients to answer their questions, provide guidance, and assist in the final steps of the enrollment process, including referral to a site, resolution of logistical issues, and understanding their financial assistance needs.

除了技术解决方案之外，Massive Bio还通过其礼宾服务提供个性化支持。一旦转诊，Massive Bio的患者关系协调员，MDs和肿瘤护士将与患者密切合作，回答他们的问题，提供指导，并协助注册过程的最后步骤，包括转诊到网站，解决后勤问题，并了解他们的财务援助需求。

This ensures a smooth transition from referral to trial participation, addressing any concerns and logistical issues that may arise..

这确保了从转诊到参与试验的顺利过渡，解决了可能出现的任何问题和后勤问题。。

“Patient Connect empowers people to intuitively navigate the clinical trial enrollment process, keeping patients connected to their physicians and loved ones throughout their personal journey,” said Oz Hüner, Chief Product Officer of Massive Bio.

Massive Bio首席产品官Oz Hüner说：“患者连接使人们能够直观地导航临床试验注册过程，使患者在整个个人旅程中与医生和亲人保持联系。”。

Engaging with oncologists and hematologists is as important as patient engagement. Using Massive Bio Clinical Network, treating physicians are able to review their patient’s pre-screening results and easily start and monitor their patient’s enrollment process. Massive Bio uniquely combines patient and provider engagement to increase clinical trial enrollment globally, a first in the industry..

与肿瘤学家和血液学家合作与患者参与一样重要。通过使用大规模的生物临床网络，主治医师能够查看患者的预筛查结果，并轻松启动和监控患者的登记过程。。。

To learn more about Massive Bio Patient Connect, please visit www.massivebio.com/patient-connect. Physicians interested in Massive Bio Clinical Network may learn more and register by visiting www.massivebio.com/clinical-network.

要了解有关Massive Bio Patient Connect的更多信息，请访问www.massivebio.com/Patient-Connect。对大规模生物临床网络感兴趣的医生可以通过访问www.massivebio.com/Clinical-Network了解更多信息并注册。

About Massive Bio:

关于Massive Bio：

Massive Bio’s vision is to transform the entire pharmaceutical value chain with disruptive solutions that enhance the ecosystem from drug development to commercialization. As a unique AI-enabled real-world data company, Massive Bio addresses all friction points in the end-to-end patient journey, facilitating patient access to advanced treatment options and optimizing drug clinical trials and commercialization for pharmaceutical companies.

Massive Bio的愿景是通过颠覆性解决方案改变整个制药价值链，从而增强从药物开发到商业化的生态系统。作为一家独特的人工智能支持的现实世界数据公司，Massive Bio解决了端到端患者旅程中的所有摩擦点，促进了患者获得先进治疗方案，并优化了药物临床试验和制药公司的商业化。

Committed to breaking down barriers and enhancing equitable access to clinical trials, Massive Bio fosters value-based oncology decisions and facilitates data-driven cancer treatment. Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio has served over four dozen pharmaceutical companies, contract research organizations, and hospital networks.

Massive Bio致力于打破障碍，提高临床试验的公平性，促进基于价值的肿瘤学决策，并促进数据驱动的癌症治疗。Massive Bio成立于2015年，由临床、技术和并购高管组成，为40多家制药公司、合同研究机构和医院网络提供服务。

It is a founding member of the CancerX public-private partnership and participates in the Cancer Moonshot White House initiative. Massive Bio has earned recognition from the National Cancer Institute through an SBIR contract. Today, Massive Bio has a global presence with over 100 employees across 17 countries.

它是CancerX公私合作伙伴关系的创始成员，并参与了白宫癌症登月计划。。如今，Massive Bio在全球17个国家拥有100多名员工。

For further details, please visit our website www.massivebio.com and connect with us on our social media channels..

有关更多详细信息，请访问我们的网站www.massivebio.com，并通过我们的社交媒体渠道与我们联系。。